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1. Introduction
Hydrogels are water-swollen polymer networks formed by cross-
linked polymer chains and are ubiquitous in nature. The slime-
producing, eel-like hagfish releases a mucin-based hydrogel 
to choke its predators,[1] and humans rely on a hydrogel 
network composed of collagen and hyaluronic acid (HA) 
to form the vitreous humor of the eye.[2] However, hydrogels 
can also be formed from synthetic polymers, opening a myriad 
of synthesis strategies to create materials with widely dif-
ferent physical, chemical, and biological properties. Because of 
their hydrophilicity and chemical amenability, hydrogels have 
long been an exciting and promising tool in biomaterials and 
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biomedical research. Indeed, their use 
in applications including as soft contact 
lenses for correcting vision was first pro-
posed by Czech chemists Wichterle and 
Lím more than 50 years ago.[3] However, 
the rise of the fields of drug delivery, cell 
therapies, and tissue engineering (TE) over 
the past decades has widened the scope of 
their potential applications and hydrogels 
are now being developed to do everything 
from repair articular cartilage damaged by 
osteoarthritis,[4,5] to regenerate heart tissue 
after myocardial infarction.[6]
The native extracellular matrix (ECM) 
can be thought of as a cross-linked, hydro-
philic polymer network. Therefore, at a 
fundamental level, hydrogels, whether 
synthetic or naturally derived, are in many 
ways akin to the native ECM. Many hydro-
gels can also be cross-linked under mild 
conditions, allowing for the encapsulation 
of live cells. Because of these features, 
hydrogels have been proposed as 3D ex 
vivo tissue models. The 3D network of 
hydrogels, which enable encapsulated cells to interact with their 
environment in all directions, often better replicates the environ-
ment cells experience within tissues compared to 2D cultures, 
which can force cells to adopt unnatural polarities. Hydrogels’ 
chemical amenability also allows them to be formed with widely 
different physical properties, including stiffness, and biological 
functionalizations mediated by the incorporation of adhesive 
and degradable peptide sequences, which can mimic many bio-
logical and physical properties of the native ECM. Hydrogels 
are also being explored as therapeutic delivery vehicles. Acel-
lular hydrogels can be designed for site-specific slow release of 
drugs or other bioactive molecules, such as growth factors. And 
hydrogels with encapsulated cells are being developed for TE 
and other regenerative strategies. By modulating their physical 
and biological properties, hydrogels can coax encapsulated cells 
to form new tissues. They can also retain therapeutic cells at 
specific tissue sites, allowing them to mediate repair either indi-
rectly via paracrine signaling, or directly, by differentiating and 
producing tissue.
Despite these exciting developments, hydrogels have also 
been subject to criticism. Although their hydrophilic proper-
ties are akin to that of many native tissue ECMs, early gen-
erations of hydrogels used for many biomedical applications 
lacked important properties of native tissues that are known to 
be key in directing cell behavior. Native tissues, for example, 
are heterogeneous in structure, respond dynamically to their 
© 2018 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, 
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surrounding environment,[7] can often self-heal in response to 
injury,[8] and their mechanical properties tend to be nonlinear 
and often viscoelastic.[9] Conversely, many standard hydrogels, 
particularly those formed from synthetic polymers, are static, 
only sparingly adaptable to cell-mediated changes, and their 
mechanical properties are often linearly elastic. Moreover, 
many hydrogels are structurally homogeneous and cannot 
mimic the architectural and mechanical complexity of native 
tissues at multiple length scales. In general, many hydrogels 
also have relatively weak mechanical properties for TE applica-
tions. For example, hydrogels have been widely proposed for 
cartilage TE, however, their tensile and compressive properties 
often do not match those of the native tissue.[10]
The last decade, however, has witnessed an explosion of 
new chemistries, designs, and fabrication methods that have 
returned hydrogels to the forefront of cutting-edge bioma-
terials research (Table 1). Researchers are exploring a new 
generation of hydrogel-based biomaterials that better act as 
tissue models by mimicking the time-dependent and non-
linear properties that govern the behavior of native tissues. 
They are also designing materials for regeneration that 
interact with cells as never before. Not just delivering cells 
locally, but doing so in a controlled way, or designing chem-
istries that recruit cells to the material. 3D printing methods 
have also been developed to precisely control tissue architec-
ture and cell localization within tissue-like constructs, and 
for the first time, have allowed for the creation of complex 
tissue-like structures with vasculature. These next genera-
tion materials require delivery methods to match. Therefore, 
researchers have also been exploring exciting means for in 
situ cross-linking and injectable delivery. And indeed, hydro-
gels that aim to repair defects in articular cartilage and 
restore damaged heart tissue after myocardial infarction are 
now in preclinical and clinical trials.
Here, we review some of the state-of-the-art advances in the 
design and fabrication of hydrogels for regenerative medicine 
(Figure 1). We specifically focus on where exciting new chemi-
stries and manufacturing techniques are allowing researchers 
to make materials that better mimic the native tissue. We also 
address how controlled chemistries are allowing for more 
precise engineering of spatial and time-dependent proper-
ties in these hydrogels with a look to how these materials will 
eventually translate to clinical applications.
2. Hydrogels as Ex Vivo Tissue Models
It was not long after George Otto Gey managed to cul-
ture Henrietta Lacks’s cervical cancer cells in a dish[11] that 
researchers realized that cells behave differently in the body 
than they do on tissue culture plastic.[12] Many cells on 2D sur-
faces adopt unnatural polarities and create large focal adhesion 
plaques, behaviors (among a myriad others), which fundamen-
tally differ when cells are within native tissues.[12] Therefore, 
to fundamentally understand how cells respond in health and 
disease to a variety of stimuli, it is important to develop culture 
systems which better mimic cells’ normal 3D environments. 
The 3D structure and ECM-like properties of hydrogels make 
them one of the best tools biologists have for doing exactly this.
Over the past 15 years, the fields of cell and stem cell biology 
have uncovered an increasing role for physical properties of the 
ECM in directing cell behaviors. Indeed, materials that control 
cell morphology, elastic, and viscoelastic properties of cells’ sub-
strates, and micro- and nanoscale topographies, among other 
factors, have been shown to play important roles in directing 
stem cell differentiation and driving other fundamental cell 
behaviors. As our understanding of how physical properties 
of the ECM direct stem cell fate and tissue formation have 
grown, we have witnessed a concomitant development of bio-
materials that mimic such properties. However, translating 
behaviors on 2D surfaces to 3D tissue-like platforms have 
revealed additional complexities. In 3D, not only do substrate 
stiffness and topo graphy play important roles, but also cell-
mediated matrix degradability, cell migration, and physical 
constraint.[13,14] The field is currently developing new hydro-
gels that allow us to understand the interplay between these 
factors, and how they independently and synergistically direct 
cell behavior.
2.1. Incorporating Adhesive Motifs
With the notable exception of blood cells, most cells in the 
body are anchorage dependent. That is, they must adhere to a 
substrate to survive. Anchorage-dependent cells deprived of a 
substrate on which to attach will undergo a specialized form 
of apoptosis called anoikis.[15] Engaging integrin receptors—
cells’ transmembrane structures that mediate attachment to 
extracellular substrates—will not rescue viability[16] because 
most cells have to be physically tethered to a surface to sur-
vive. In vitro, this substrate is normally tissue culture plastic, 
a plasma-treated polystyrene surface that adsorbs proteins 
onto which cells attach.[17] In the body, this substrate is often 
the ECM, a network of insoluble protein biopolymers, which 
can contain binding sites that mediate interactions with cells. 
Hydrogels formed from many ECM-derived biopolymers such 
as collagen contain abundant binding sites that mediate inter-
actions between the hydrogel and encapsulated cells. However, 
synthetic polymers such as poly(ethylene glycol) (PEG) 
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and even biologically derived matrices such as alginate do not. 
Therefore, adhesive motifs need to be incorporated into hydro-
gels to allow attachment to their surroundings and mediate 
cell viability.
Hydrogels intended for cell encapsulation that are lacking in 
their own binding motifs are often chemically modified to dis-
play them. Standard strategies include tethering proteins or pep-
tides with integrin-binding sequences to the polymer backbone 
of the hydrogel.[18,19] For example, multiarm PEG molecules 
are often conjugated to enable some arms to engage in cross-
linking reactions while others present pendant adhesive motifs. 
Typical natural ECM components incorporated into hydrogels 
include collagen, fibronectin, and laminin. While common 
adhesive peptide sequences include fibronectin-derived RGD 
and LDV and laminin-derived IKVAV and YIGSR.[20] Cell–ECM 
binding interactions can trigger specific signaling cascades 
within the cell, including those that control differentiation. This 
behavior is mediated through integrins, which only recognize 
and interact with specific peptide sequences within the ECM. 
For example, although human marrow stromal cell (often 
referred to as mesenchymal stem cells, MSC) express a wide 
range of integrins, including α1, α2, α3, α4, α5, αV, β2, and β1, 
it is their engagement with RGD sequence-containing peptides 
that supports their long-term viability. However, as human 
MSC (hMSC) differentiate, their integrin expression patterns 
change, and the binding of specific motifs drives lineage speci-
fication. For example, the IKVAV binding peptide sequence, 
which engages α4β1 and α6β1 integrins, promotes osteogenesis 
to a greater extent than that induced by YIGSR and RRETAWA 
binding sequences. Similarly, both the IKVAV and RRETAWA 
sequences, which bind to α4β1/α6β1 and α5β1 integrins, 
respectively, are more conducive for adipogenesis than the RGD 
binding sequence alone.[19,21] Although beyond the scope of this 
Adv. Healthcare Mater. 2018, 1700939
Table 1. Table highlighting important design criteria for biological hydrogels.
Design criteria Design variables Factors to consider
Material Type of material
•	 Natural:	collagen,	fibrin,	and	alginate
•	 Synthetic:	polyacrylamide,	polyethylene	glycol	(PEG)
•	 Hybrid	materials:	hyaluronic	acid	(HA),	polypeptides
•	 Biocompatible
•	 Template	for	tissue	growth	in	3D
•	 Allow	for	vascularization	(microporous)
•	 Appropriate	mechanical	properties
•	 Biodegradable—reabsorbs	at	same	rate	as	regeneration
Cross-linking strategies Physical (noncovalent) cross-linking:
•	 Ionic	interactions—charge	interactions
•	 Peptide	based	self-assembly—Supramolecular	structures,	e.g.,	β-sheets
Chemical (covalent) cross-linking:
•	 Chain	growth	polymerization—via	redox	or	photoinitiation	(UV)
•	 Click	chemistry—	e.g.,	Michael-type	addition
•	 Enzyme-mediated	cross-linking—e.g.,	transglutaminase	and	tyrosinase
•	 Speed	of	cross-linking
•	 Complexity	of	reagents
•	 Appropriate	for	cell	encapsulation—cytocompatible
•	 Precise	control	of	microstructure	(supramolecular)
•	 Cross-linking	density	(network	porosity)
•	 Control	of	mechanical	properties	such	as:
o Elasticity/viscoelasticity
o Viscosity
Delivery methods •	 Injectable—in	situ	forming	hydrogels
•	 Hydrogel	patch—Such	as	transdermal	or	epicardial
•	 Implant—preformed	hydrogel	scaffold—e.g.,	bioprinted
•	 Invasiveness	of	the	procedure
•	 Target	organ
•	 Aim	of	treatment—drug	delivery,	tissue	regeneration,	etc.
Biological agents Cell encapsulation:
•	 Mesenchymal	stem	cells	(MSC)	or	induced	pluripotent	stem	cells	(iPSC)
•	 Autologous	or	allogenic
•	 Immunogenicity
•	 Safety	(following	genetic	manipulation)
•	 Cost	and	availability
Biological molecules:
•	 Growth	factors,	immunomodulatory,	gene	therapy
•	 Dosage
•	 Choice	of	biological	agent(s)
•	 Timing	(sustained	release	vs	temporally	specific)
Figure 1. Summary of state-of-the-art strategies for hydrogel design and fab-
rication and their applications in regenerative medicine. Advancements in 
both biology and material science have allowed for the development of com-
plex	 regenerative	 strategies.	 Green:	 Researchers	 are	 designing	 hydrogels	
with various delivery strategies tailored for each biological application. Red: 
Our increased understanding of mechanobiology is driving the development 
of hydrogels that can aid biologists in understanding these fundamental 
processes,	and	allow	researchers	to	exploit	them	to	drive	cell	response	for	
regeneration. Yellow: Advanced manufacturing technologies are allowing 
for the development of hydrogels with tissue-specific architectures and bio-
logical functionalities. Orange: Acellular hydrogels are being developed to 
both deliver relevant biological molecules and direct host tissue response.
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review, the reader is referred to excellent summaries of the role 
of integrin binding in controlling cell behavior.[22]
Moreover, while the composition of the ECM and ECM- 
mimicking peptides incorporated within hydrogels is clearly 
important in modulating cell attachment and downstream cell 
signaling, the spacing of integrin binding motifs may also be 
important. On 2D surfaces, cells are known to be highly sensitive to 
interligand spacing. For example, increasing interligand distances 
from 58 to 73 nm has been shown to alter cell morphology.[23] 
Moreover, smaller interligand spacings appear to induce a bias in 
MSC differentiation toward osteogenesis.[24] Most 3D hydrogels 
allow for modulation of overall ligand density, and there is evi-
dence that PEG hydrogels modified with dangling RGD-binding 
sequences do not support cellular interactions below certain 
concentrations;[25] however, the role of precise ligand spacing, 
akin to those that have been examined on 2D surfaces, has only 
recently been explored in 3D. Pashuck et al. synthesized pep-
tides that utilized a β-sheet motif to self-assemble into nanofiber 
hydrogels.[26] As the β-sheet peptide’s backbone spacing was 
known, adhesive epitopes (RGDS and PHSRN) were control-
lably spaced at distances between 0.7 and 6.2 nm. Endothelial 
cells encapsulated within hydrogels with spacings of 3.2 nm, 
which mimicked the spacing found in fibronectin, showed signi-
ficant upregulation of the α5 integrin subunit and adopted 
more spread morpho logies when compared to cells encapsu-
lated within hydrogels with 6.2 nm spacing. Ideal networks with 
orthogonal geometries are similarly being explored to further 
unravel the role, if any, of 3D spacing cues in directing other cell 
responses, such as differentiation.[27]
2.2. Controlling Cell Morphology
2D cell shape has long been known to regulate cell behaviors. 
Watt et al.[28] determined that cell morphology regulated epi-
dermal cell lineage commitment in the 1980s, and McBeath 
et al.[29] reported that hMSC morphology regulated a fate switch 
between adipogenesis and osteogenesis through Ras homolog 
gene family member A/Rho-associated, coiled-coil containing 
protein kinase 1 (RhoA/ROCK) signaling. Many of these find-
ings were made possible by a technique called microcontact 
printing, in which 2D patterns of adhesive motifs are stamped 
onto an otherwise nonadhesive surface, allowing precise control 
of cell size and shape. Using this technique, they and others 
established that in MSC, spread cell morphologies promote 
cytoskeletal tension, which upregulates osteogenesis, and round 
morphologies promote adipogenesis.
Mechanoregulation of MSC fate has recently been asso-
ciated with the downstream hippo pathway effectors Yes-
associated protein (Yap) and transcriptional co-activator with 
PDZ-binding motif (Taz).[30] Spread MSC morphologies pro-
mote nuclear localization of Yap/Taz, while restricting cell 
spreading, inhibits cytoskeletal tension, excludes Yap/Taz from 
cell nuclei, and prompts MSC to adopt adipogenic phenotypes. 
However, while Yap/Taz signaling appears to be a key medi-
ator of the conversion of physical to chemical signals, other 
candidates such as lamin-A and the retinoic acid pathway are 
also thought to be important in the mechanoregulation of a 
plethora of cell responses.[31] Stem cells other than MSC 
have similarly been shown to be mechanoresponsive. Changes 
in actin cytoskeleton organization, for example, have been 
shown to induce epidermal stem cell differentiation.[32] Indeed, 
when spreading is restricted, keratinocytes differentiate by 
regulating serum response factor (SRF). SRF then targets FOS 
and JUNB, members of the AP-1 family of transcription factors, 
which are known to play important roles in epidermal terminal 
differentiation.[32] Although a more detailed discussion is out-
side the scope of this review, putative signaling mechanisms by 
which cells sense and respond to their physical environment 
have been previously explored.[33]
In addition to showing that cell size influences differentiation, 
researchers have also used microcontact printing to demonstrate 
that pattern shape, and specifically shape perimeter, also directs 
lineage specification. MSC on more rounded patterns that have 
smaller perimeters adopt adipogenic phenotypes, while MSC on 
patterns with steeper angles that have larger perimeters, such 
as star shapes, promote osteogenesis, even when total cell area 
is kept constant.[34] For a comprehensive review, the reader is 
referred to an excellent review by Vogel and Sheetz.[35]
While control of cell morphology in 2D is relatively straightfor-
ward and has revealed clear effects on MSC lineage specification, 
controlling cell morphology in 3D hydrogels is more complex. On 
2D surfaces, cells face no external barriers when assuming their 
morphologies. However, in both native tissues and within 3D cul-
ture, cell morphology is limited by the presence of the ECM or 
encapsulating material. In 3D hydrogels, morphology is generally 
controlled through degradation either by incorporating enzyme-
mediated degradation into the hydrogel, or directly 3D patterning 
degradative motifs. To change their morphology in this context, 
cells often degrade their surroundings by secreting enzymes, 
which target specific proteins in their ECM. Within hydrogels 
formed from naturally derived polymers such as gelatine, col-
lagen, and fibrin, as well as polysaccharides such as HA,[36] cells 
can often degrade their surroundings as they do in native tissues. 
However, within synthetic 3D hydrogels, control of cell shape is 
often achieved by cross-linking the network with peptides con-
taining sequences that can be cleaved by cell-secreted enzymes. 
In nondegradable hydrogels, cells will often adopt round mor-
phologies, even when presented with adhesive motifs. However, 
the incorporation of matrix metalloproteinase (MMP)-degradable 
peptide sequences allows cells to adopt spread morphologies.[37] 
Controlling cell morphology through degradation can have a 
profound impact on differentiation. Indeed, hMSC encapsulated 
within RGD-modified HA-based hydrogels that are degradable 
adopt spread morpho logies, generate cytoskeletal tension and 
undergo osteogenic differentiation,[38] while limiting degradation 
prompts cells to adopt adipogenic phenotypes.
The alternative strategy to control cell morphologies and 
migration within 3D hydrogels is to spatially control the avail-
ability of degradable and adhesive sites. Recently, this has 
been achieved with the use of light-sensitive chemistries in 
combination with patterned UV irradiation and laser exposure 
(Figure 2).[39] Researchers accomplished this by incorporating 
nitrobenzyl ether derivatives into hydrogels, which cleave 
upon exposure to 365 nm light. The light-sensitive groups 
are then linked to adhesion and/or cross-linking components 
of the hydrogel. By carefully focusing a laser at specific loca-
tions within the 3D hydrogel, degradation can be induced by 
Adv. Healthcare Mater. 2018, 1700939
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breaking the cross-links that hold the hydrogel together, or cell 
adhesion can be inhibited by cleaving cell-adhesive peptides 
from the hydrogel network. Encapsulated cells detect the light-
mediated degradation by altering their migratory behavior; and 
sense changes in adhesive ligands by modifying their mor-
phologies. This technology is particularly promising because it 
allows for patterning of cell adhesion and degradability in a 3D 
spatiotemporal manner with micrometer-scale resolution.
2.3. Modulating Substrate Stiffness
In 2006, Engler et al.[40] reported that 2D substrate stiffness had 
a profound effect on the lineage commitment of hMSC in the 
absence of chemical induction. Soft substrates that mimicked 
the stiffness of brain tissue promoted neurogenesis, stiffer sub-
strates more akin to skeletal muscle prompted cells to become 
myogenic, and stiff substrates that matched the mechanical 
properties of the developing osteon drove cells to adopt osteo-
genic phenotypes. The implication was that cells physically 
“felt” the stiffness of their underlying matrix and used this 
information as an important driver of lineage specification. 
Although only shown on 2D substrates, this finding opened the 
possibility that stiffness itself could be exploited to direct stem 
cell differentiation. As a result, there has been tremendous 
interest in developing hydrogel systems that allow researchers 
to understand the role of 3D stiffness in directing the differen-
tiation of MSC in ex vivo tissue models.
Although the role of 2D stiffness in regulating stem cell fate 
has been clear for more than a decade,[40–42] the role of stiffness 
in directing MSC lineage specification in 3D is more complex. 
Using a nondegradable, RGD-modified, ionically cross-linked 
alginate-based hydrogel, Huebsch et al. showed that like on 
2D surfaces, MSC responded to the stiffness of their surrounds 
in 3D.[43] That is, stiffer hydrogels promoted osteogenesis 
and softer adipogenesis. However, unlike in 2D, stiffness did 
not impact cell morphology, and all cells maintained round 
morphologies independent of hydrogel stiffness. They instead 
showed that differentiation depended on the clustering of inte-
grin-binding motifs within the hydrogels, which was dependent 
on substrate stiffness.
However, in degradable hydrogels formed from RGD-modified, 
methacrylated HA, degradation-mediated cellular traction was 
found to direct MSC differentiation, independent of substrate 
stiffness.[38] That is, hMSC adopted adipogenic phenotypes 
over a wide range of stiffnesses (4.91–91.64 kPa) in nonde-
gradable RGD-modified methacrylated HA hydrogels, but 
when hydrogels were modified to allow cell-mediated degrada-
tion, hMSC generated cytoskeletal tension (hydrogel stiffness 
≈3–5 kPa) and differentiated down the osteogenic lineage. 
The authors attributed these findings to the relative differ-
ences between ionically and covalently cross-linked hydrogels. 
However, the role of stiffness in the differentiation of MSC in 
3D hydrogel cultures remains controversial and other factors 
could indeed also be playing important roles. For instance, 
time-dependent effects in hydrogel systems could confound 
results. Cells modify their surrounding matrix by secreting 
proteins extracellularly over time when encapsulated in 3D.[44] 
Moreover, 3D hydrogel matrices that allow for cell-mediated 
degradability will undergo time-dependent changes in local and 
perhaps bulk stiffness as the hydrogel degrades, which may 
influence cell response.
In summary, utilizing modifiable hydrogels to understand 
the contribution of stiffness to lineage specification can be 
fraught. While nondegradable systems will likely provide 
insight into the differentiation of cells that reside in tissues 
in which matrix turnover is slow, degradable systems may 
better mimic native tissue niches that experience quicker ECM 
turnover. Matrix degradation is known to play central roles in 
development, stem cell differentiation, and tissue formation. 
For example, in the developing embryo, cells migrate through 
3D matrices, undergo cell shape changes concomitant with 
differentiation, and remodel their ECM. These behaviors are, 
Adv. Healthcare Mater. 2018, 1700939
Figure 2. Microscale photoreversible patterning of proteins within 
3D hydrogels. A,B) Fluorescence confocal microscopy images of dual-
protein patterning within hydrogels. Hydrogels were patterned with 
covalently	 immobilized	 interlocking	 chains	 of	 red	 protein	 while	 sur-
rounding areas were labelled with a green protein. Scale bars = 50 µm. 
C) Hydrogel with 3D patterned protein in a staircase pattern. Patterning 
was achieved in 3D using focused laser pulses and by varying the 
multiphoton laser-scanning conditions, resulting in highly ordered posi-
tioning of proteins. Scale bar = 150 µm. Adapted with permission.[186] 
Copyright 2015, Nature Publishing Group.
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in many cases, dependent on the degradability of the native 
ECM.[45] When ECM degradation in the developing mouse 
embryo is repressed by MMP inhibitors, morphogenesis 
and development of oil-induced deciduomas are slowed, and 
changes take place in precursor stromal cell differentiation and 
expansion.[46] Cell-mediated matrix degradation is also impor-
tant in wound healing. When matrix degradation was inhibited 
by the broad-spectrum MMP inhibitor BB-94 in full-thickness 
skin excisional wounds in rats, myofibroblast formation, stromal 
cell proliferation, blood vessel formation, and epithelial wound 
coverage, key components of healthy skin wound healing, were 
all delayed.[47] In short, many tissues are highly dynamic and 
degradation and ECM remodeling are key tools they utilize to 
maintain homeostasis. Therefore, incorporation of this feature 
into ex vivo models may be important to fully understand and 
exploit tissue regeneration.
2.4. Integrating Time-Dependent and Self-Healing Properties
Many tissues in the body, particularly soft tissues, exhibit 
viscoelastic mechanical properties. That is, they behave simul-
taneously as both an elastic material and a viscous fluid. 
Viscoelastic materials will continue to deform, or creep, if left 
under an applied load, or undergo stress relaxation, whereby 
they exert less stress over time, when placed under a constant 
deformation.[42] Such properties are well described in muscu-
loskeletal tissues such as ligament and tendon where these 
behaviors play important roles in normal joint function.[48]
Until recently, most synthetic hydrogels examined for 
directing cell behavior in response to mechanical properties 
such as stiffness were linearly elastic. That is, they possessed 
a linear relationship between stress and strain, and they 
returned to their original shape upon unloading, without loss 
of energy. However, it is now becoming apparent that cells, 
both on 2D surfaces and when encapsulated within 3D hydro-
gels, respond not only to the elastic but also viscoelastic prop-
erties of their underlying or surrounding matrix.[49,50] Chaud-
huri et al. recently showed that a human osteosarcoma cell 
line (U2OS) responded differently when cultured on the sur-
face of viscoelastic ionically cross-linking alginate hydrogels 
compared to when they were on purely elastic hydrogels of the 
same initial stiffness that were formed from covalently cross-
linking the alginate.[49] Indeed, counter to the intuitive expec-
tation that cells would integrate the modulus of a relaxing 
substrate over time and behave as if they were on a softer 
substrate, U2OS cells actually spread more on substrates that 
underwent stress relaxation. The authors suggested that cells’ 
ability to respond to viscoelasticity is likely a fundamental bio-
logical property.
Similarly intriguing observations were reported when cells 
were encapsulated within 3D viscoelastic hydrogels.[51] In RGD-
modified alginate hydrogels, the proliferation and morphology 
of encapsulated 3T3 fibroblasts were highly dependent on the 
time scale of stress relaxation. That is, in matrices that under-
went fast relaxation, cells tended to spread more and prolif-
erate, while slowly relaxing materials prompted cells to adopt 
round morphologies and inhibited proliferation. Similarly, 
when murine MSC were encapsulated within fast-relaxing 
hydrogels, they differentiated to osteoblasts that formed a 
mineralized collagen type I-rich matrix, but in slowly relaxing 
hydrogels, MSC adopted adipogenic phenotypes. The authors 
attributed these observations to the ability of encapsulated 
cells to cluster RGD ligands in the faster-relaxing hydrogels. 
They also argued that in fast-relaxing hydrogels, MSC were 
more able to mechanically remodel their surrounding matrix. 
Interestingly, the authors correlated increased Yap nuclear 
localization with faster-relaxing hydrogels, independent of 
hydrogel stiffness. However, unlike in 2D systems where 
nuclear localization has been correlated with osteogenesis,[30] 
substrate viscoelasticity-mediated nuclear translocation of Yap, 
did not itself direct lineage specification.
In addition to viscoelastic hydrogels, much interest has 
also been focused on creating viscoelastic hydrogels that 
are also self-healing, and so can mimic repair processes that 
take place in native tissues. These hydrogels are typically 
composed of macromolecules that are noncovalently bonded 
together via molecular recognition motifs such as hydrophobic 
interactions, π–π interactions, hydrogen bonding, metal chela-
tion, or van der Waals interactions.[52] Various mechanisms 
have been exploited to create self-healing hydrogels, but the 
basic premise is that interactions between individual molecules 
are locally dynamic, but the bulk hydrogel is globally stable. 
The noncovalent and dynamic nature of these interactions not 
only make these hydrogels self-healing, but also easily inject-
able and shear thinning. Shear thinning materials can protect 
encapsulated cells against fluid shear forces generated during 
injection by “un-cross-linking” under shear and re-establishing 
cross-links when shear is removed.[53] A key advantage of shear 
thinning hydrogels formed through physical interactions is that 
they can be formed ex vivo, prior to injection. In this context, 
the influence of the surrounding tissues on hydrogel gelation 
is negligible, in contrast to hydrogel systems with liquid pre-
cursors, whose gelation may be affected by various constituents 
of the native milieu. Self-healing hydrogels are yet to be fully 
exploited to understand cell-material interactions relevant to 
TE and regenerative medicine. For a comprehensive review of 
self-healing biomaterials, the reader is referred to an excellent 
review by Webber et al.[52]
3. Hydrogels with Tissue-Specific Mimicry 
and Functionality
In addition to developing materials that can be used as ex 
vivo tissue models, there is also tremendous interest in using 
hydrogels directly in TE. TE aims to treat a myriad of diseases 
by replacing lost/damaged tissue with living constructs created 
in the laboratory. The applications of TE range from restoring 
tissue lost to myocardial infarction, to filling bone defects with 
cell-laden scaffolds that respond to load and remodel over 
time. However, the repair/regeneration of complex tissues and 
organs requires approaches that are specific to each tissue. 
When designing a hydrogel that can mediate tissue repair, sev-
eral parameters are key to consider, including the tissue archi-
tecture, mechanical and biological cues, and cell type (Figure 3). 
Indeed, advances in all three areas are likely key in ensuring 
effective regeneration.
Adv. Healthcare Mater. 2018, 1700939
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3.1. Incorporating Tissue-Specific Architectures 
into Hydrogel Design
Whereas many early generations of hydrogels were homoge-
neous, isotropic structures that bore little resemblance to com-
plex native tissues, the design of tissue-specific architects for TE 
has taken a leap over the past decade with the advent and growth 
of 3D bioprinting. Bioprinting is a computer-assisted technology, 
which can assemble tissues-like constructs through precise 
spatial localization of biological materials in 3D. Bioprinting 
technologies utilize “bioinks” often composed of different hydro-
gels, with or without encapsulated cells.[54]
Within the field of bioprinting several different methods are 
available, many of which are amenable to hydrogel technolo-
gies. The most common include microextrusion, inkjet, and 
light-induced methods, which include stereolithography and 
laser-assisted bioprinting (LAB) (Figure 4). For a detailed over-
view, the reader is referred to excellent reviews in this area.[54–56] 
Of these technologies, inkjet bioprinting was the first to be 
developed.[55] Advantages of this system include its high 
printing speed and low cost; however, thermal and mechan-
ical stresses can damage encapsulated cells.[54,57] Another 
limitation of inkjet systems is their relatively poor capacity 
to handle materials of high viscosities, which can limit their 
ability to print hydrogels with high cell densities.[54,55] Inkjet 
printing has been shown to be effective in the regeneration of 
both skin[58] and cartilage.[59,60] For example, Markstedt et al. 
used a nanocellulose bioink to produce precise anatomically 
shaped cartilage structures such as the human ear and sheep 
meniscus.[60]
Adv. Healthcare Mater. 2018, 1700939
Figure 3. Tissue-specific hydrogel design considerations. When developing tissue-specific hydrogels, a number of factors should be considered. 
For	example,	the	choice	of	cell	type	and	biological	factors	will	be	dictated	by	the	biological	application.	However,	the	emergence	of	new	technologies,	
such	as	those	that	allow	for	the	creation	of	patient-specific	stem	cells,	for	example	iPSC,	may	allow	for	additional	opportunities.	Hydrogel	material	
choice is not always straightforward and may be dictated by a range of factors, such as amenability to bioprinting, the need to form a tissue interface 
or the necessity of tissue-specific functionality.
www.advancedsciencenews.com www.advhealthmat.de
1700939 (8 of 22) © 2018 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Microextrusion printing works on a similar basis to inkjet, 
however, it allows materials of higher viscosities to be depos-
ited. This is important as it allows for the deposition of high-
density cell solutions, which are key in replicating many 
highly cellular native tissues.[54] This strategy has been used to 
print aortic valve conduits,[61] vascular grafts,[62] and cartilage 
constructs,[63] among other tissues. LAB systems are lauded 
for their high resolution as they can produce resolutions on 
the microscale (≈10 µm), which is important for mimicking 
many structures of native tissues at or near the scale of the 
single cell.[64] An advantage is that these systems are nozzle 
free, which precludes issues with clogging that have been 
problematic with the other bioprinting technologies.[54] Ste-
reolithography, like LAB, uses light to print and works by 
selectively solidifying bioinks in a layer-by-layer process.[55] 
While lacking the high resolution of LAB methodologies 
(≈25 µm), this layer-by-layer process can often increase 
printing speeds.[56]
In situ printing, in which materials combined with cells are 
printed directly into a tissue defect (as opposed to requiring 
later surgical implantation) is also emerging as a method to 
create materials in situ with precise architectures to drive 
tissue-specific repair. In comparison to classic bioprinting strat-
egies, in situ bioprinting has several advantages, most notably 
of which is that it potentially allows for the fast, direct delivery 
of cells. This style of printing is often envisioned for future 
clinical applications, in which fully automated robotic printers 
controlled by surgeons directly print architecturally controlled, 
cell-laden constructs at the site of injury. In situ printing of 
amniotic fluid-derived stem cells and MSC has proven effective 
in mediating wound closure in a severe skin wound model.[58] 
Work by Keriquel et al. have similarly demonstrated a LAB-
based bioprinting system in which in situ printing of MSC 
collagen/hydroxyapatite bioink was able to stimulate bone 
regeneration in a calvarial defect model in a mouse.[65] 
The authors were able to print precise scaffold patterns into 
the site of injury, and cells within the printed scaffold main-
tained good cell viability.[65]
While bioprinting allows for specific design of tissue 
constructs, one drawback of the technology has been its 
scalability. That is, there has been a limit thus far in printing 
large, structurally sound, biological constructs that are needed 
to repair/replace many tissues.[66] However, one pioneering 
study demonstrated an integrated tissue-organ printer in which 
human-scale tissue constructs could be printed (Figure 5).[66]  
This bioprinting system simultaneously dispensed composite 
cell-laden hydrogels consisting of fibrinogen, HA, gelatin and 
glycerol, alongside a synthetic biodegradable polymer and an 
outer sacrificial acellular hydrogel mold. This mold provided 
the tissue constructs with enough rigidity to ensure the con-
struct retained its shape, but could then be easily removed. 
A lattice of microchannels was also incorporated into the 
design to allow for nutrient and oxygen diffusion within the 
printed construct.[66] The authors also implemented CT and 
MRI imaging to help design the scaffold. Raw imaging data 
was processed using computer-aided manufacturing tools and 
mathematical modeling to produce 3D rendered models.[66] 
This allowed them to capture architectural intricacies, ena-
bling them to print calvarial bone, ear, cartilage, and skeletal 
muscle.
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Figure 4.	 Examples	of	different	bioprinting	methods.	A)	Inkjet	bioprinters	deposit	small	droplets	of	hydrogel	and	cells	to	build	tissue	layer-by-layer.	
B)	Microextrusion	bioprinters	deposit	a	cell-laden	liquid	solution	via	pneumatic	or	manual	force.	C)	Laser-assisted	bioprinting	uses	a	laser	to	rapidly	
heat a donor layer (green), which forms a bubble propelling the bioink onto the substrate. D) Stereolithography bioprinters use UV or visible light to 
selectively cross-link bioinks layer by layer to build a 3D construct.
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Beyond bioprinting, other methods have also shown promise 
in integrating tissue-specific architecture into hydrogels. 
One particularly promising area is that of self-healing/ 
self-integrating hydrogels. These hydrogels are based on 
dynamic chemistries and thus are potentially exciting for a 
variety of TE strategies. Hsieh et al. investigated self-healing 
hydrogels to induce blood capillary formation. An inject-
able composite hydrogel was synthesized from chitosan 
and fibrin, which through Schiff-base linkages, lent the 
hydrogel self-healing properties.[67] When seeded with vas-
cular endothelial cells, the hydrogel allowed for the forma-
tion of capillary-like structures. These self-healing hydro-
gels have several advantages, the most obvious being that 
they can repair themselves following damage. In this case, 
the composite material was also stronger and more stable 
than a fibrin only material.[67] When targeting tissue inter-
faces, self-healing hydrogels can be particularly advanta-
geous as separate hydrogel components specific to each 
tissue type can be placed adjacent to one another, which will 
then then self-heal to form a complete construct. Indeed, 
Hou et al. developed an injectable self-healing-integrating 
hydrogel for regenerating the bone–cartilage interface that 
allowed for the relatively simple spatial localization of MSC 
and chondrocytes[68] (Figure 6).
Approaches that combine 3D printing with self-healing 
hydrogels are also being developed. Highley et al., for example, 
developed a self-healing shear thinning HA-based bioink modi-
fied with adamantane and β-cyclodextrin that could then be 
printed into a “support” HA hydrogel, creating a “guest–host” 
system. The printed HA-based bioink could then be covalently 
cross-linked to form a stable structure. Due to the self-healing 
nature of this system, direct assembly (writing) of precise struc-
tures in 3D could be achieved that otherwise would not be pos-
sible with standard “layer by layer” 3D printing strategies.[69]
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Figure 5.	 Human-scale	bioprinting.	To	print	constructs	of	sufficient	size	for	eventual	 translation	 into	humans,	Kang	et	al.	developed	an	integrated	
tissue-organ	printer	 (ITOP)	 system	 in	which	 large,	 tissue-specific	 constructs	 could	 be	printed.	 a)	 The	 ITOP	 system	comprised	 three	major	 units:	 
i)	a	three-axis	stage	controller,	ii)	a	dispensing	module	composed	of	multiple	cartridges	and	a	pneumatic	pressure	controller,	and	iii)	a	closed	acrylic	
chamber with a humidifier and temperature regulator. b) Using this bioprinter, 3D scaffold architectures could be printed with both multiple cell 
types and a PCL polymer to ensure structural rigidity. c) 3D CAD models were generated from medical image data; and using CAD/CAM processing, 
the	printer	could	be	used	to	create	complex	3D	structures,	including	a	3D	human-sized	ear.	Reproduced	with	permission.[66] Copyright 2016, Nature 
Publishing Group.
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3.2. Integrating Biomimicry: the Importance  
of Mechanical and Biological Cues
In addition to mimicking the architecture of the native tissue, 
hydrogels used for tissue regeneration may also need to mimic 
other components of the tissue environment, such as mechan-
ical and biological cues. In nature, soluble cues are transported 
to cells either via the vasculature or reach cells via diffusion 
after being secreted by their neighbors. However, cells also 
receive signals by interacting with their ECM. Such interactions 
are key in providing tissue-specific signals to cells, instructing 
them to proliferate, differentiate, and secrete/degrade ECM 
proteins, among other cell behaviors.[70] Indeed, within the 
neural stem cell niche of the subventricular zone of the brain, 
proteoglycans such as heparan sulfate bind many factors key 
for adult neurogenesis, and have been implicated in the con-
trol of proliferation and migration.[71] Similarly, perlecan within 
the kidney glomerular basement membrane has been shown to 
play important roles in filtration.[72]
ECM-based signals can be similarly incorporated into hydro-
gels, most simply by forming hydrogels from tissue-specific 
ECM. This is often achieved through a two-step process in 
which ECM material is solubilized into protein monomeric 
components, which are then formed into a hydrogel via temper-
ature or pH-controlled neutralization.[73] For many complex tis-
sues, including the heart and brain, ECM-based hydrogels can 
provide important biological cues.[73,74] For example, in a stroke-
damaged rat brain model, an ECM-derived hydrogel provided 
support for human neural stem cells and allowed for generation 
of de novo tissue.[75] Pati et al. similarly bioprinted decellularized 
ECM hydrogel bioinks from heart, cartilage, and adipose 
tissues.[76] When MSC or adipose-derived stem cells were 
encapsulated within these decellularized ECM hydrogels, they 
enhanced differentiation down either the chondrogenic or adi-
pogenic lineages, in comparison to culture within collagen 
hydrogels.[76] The authors also reported enhanced myoblast mat-
uration when cells were encapsulated in heart-derived ECM.[76] 
In short, this bioprinting strategy allowed for both the precise 
architectural control of the scaffold while also incorporating 
appropriate biological signals. Another area in which ECM hydro-
gels have been successful is in the formation of human breast 
tissue.[77] 3D hydrogel scaffolds were formed from breast tissue-
specific ECM including both protein (collagen and fibronectin) 
and carbohydrate components (hyaluronan).[77] Primary human 
breast epithelial cells encapsulated within the hydrogels were 
then shown to rapidly reorganize and form mature mammary 
tissue-like structures.[77] Importantly, tissue organization was 
observed in the absence of stromal cells, which are often consid-
ered key for ECM production and morphogenesis in vivo.
One concern with ECM-derived bioinks is that they lack 
structural integrity. One way this has been addressed is by 
printing multiple materials simultaneously: i.e., coprinting a 
strong synthetic hydrogel with a weaker ECM-derived hydrogel. 
Indeed, with the development of multidispensing bioprinting 
systems, strategies such as this may be key in designing 
complex scaffolds with both the correct biological cues 
and structural integrity. One way this could be imagined is 
through further development of the bioprinting system devel-
oped by Kang et al. in which biological cues, such as ECM, are 
incorporated into the bioink, which could then be coprinted 
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Figure 6.	 Injectable	self-integrating	hydrogels	for	osteochondral	repair.	Schematic	illustration	of	a	self-healing	hydrogel	that	could	potentially	be	used	
to	 repair	 an	osteochondral	defect.	Two	 tissue-specific	hydrogel	 formulations	made	 from	 the	same	bulk	material	 are	 injected	 into	 the	damaged	 
cartilage–bone	interface.	The	shear-thinning	properties	of	the	hydrogels	would	allow	for	easy	injection	of	the	cell-containing	solutions.	Their	self-healing	
chemistries would then foster the formation of a seamless transition between the chondrogenic and osteogenic hydrogel formulations. The chondro-
genic	hydrogel	could,	 for	example,	contain	osteochondral	progenitor	cells	or	chondrocytes	and	chondrogenic	 factors	such	as	 transforming	growth	
factor β (TGFβ ), BMP and/or insulin-like growth factor (IGF) to promote cartilage-like ECM production. Whereas the osteogenic hydrogel might include 
nanoscale	hydroxyapatite	particles	and	VEGF	to	enhance	bone	regeneration.
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with a synthetic polymer and an outer sacrificial hydrogel mold 
to ensure structural rigidity (Figure 7).[66,76]
In addition to ECM, other biological factors can be incor-
porated into hydrogels to mimic biological cues of the native 
tissue, including growth factors and cytokines. Spatial control 
of these signals may be key to replicate tissue-specific pat-
terning during differentiation and recapitulate the heteroge-
neous microenvironments of the target tissue.[78] Work by Lee 
and Park addressed this issue by using a thermoresponsive 
casting process to create precise PEG hydrogel structures with 
spatial distributions of different biological cues. They showed 
that by spatially localizing signaling molecules, MSC differ-
entiation could be driven toward osteogenic, chondrogenic, 
or adipogenic lineages.[78] Moreover, by utilizing drug-releasing 
PLGA microparticles, they were also able to demonstrate sus-
tained release of biological cues.
In addition to biological cues, mechanical cues may also be 
important to direct tissue formation. As discussed above, cells 
respond to mechanical cues in their environment, such as 
stiffness. Lutolf and co-workers showed that within intestinal 
organoid cultures, a mechanically dynamic PEG-based hydrogel 
was key in regulating appropriate cell responses. An initially 
stiff matrix allowed for intestinal stem cell expansion, but when 
switched to soft, stimulated intestinal cell differentiation.[13] 
Likewise, modulation of hydrogel stiffness (7–33 kPa) has been 
shown to promote neocartilage formation from encapsulated 
cocultures of adipose-derived stem cells and neonatal chondro-
cytes. In comparison to soft hydrogels, stiffer hydrogels accel-
erated the deposition of sulphated glycosaminoglycans, a key 
component of cartilage ECM.[79]
Hydrogels can also be modulated to mimic other important 
biological stimuli. Electrical signaling, for example, is central to 
normal heart tissue function and hydrogels can be designed 
to support this. Work by Yang et al. created a homogeneous 
electronically conductive hydrogel by controlling levels of 
conductive (Poly(thiophene-3-acetic acid) and flexible (meth-
acrylated aminated gelatin) polymers. By modulating the 
ratio of the two components, they could precisely control the 
mechanical and conductive properties of 
the construct, achieving a Young’s modulus 
and electrical conductivity that were both 
similar to that of the native heart.[80] This 
advance may be crucial, as both mechanical 
and electrical mimicry are likely important in 
restoring synchronous contractile activity.[80] 
Moreover, when brown adipose-derived stem 
cells were seeded on the hydrogels, electrical 
stimulation appeared to drive cardiomyo-
genic differentiation.[80] Work by Nunes et al. 
similarly demonstrated that electrical stimu-
lation of 3D induced pluripotent stem cell 
(iPSC) cultures within a collagen gel resulted 
in the formation of 3D aligned cardiac tissue 
(“biowires”) with ultrastructural organiza-
tion and electrophysiological properties that 
better matched those of native tissue cells 
compared to controls.[81]
3.3. Incorporating Multiple Cell Types into 
Complex Constructs
Besides utilizing a scaffold with appropriate 
mechanical and biological cues, the choice of 
cells in regenerative applications is essential. 
In addition to MSC, iPSC are also a prom-
ising option in hydrogel-based regenerative 
strategies as iPSC technology allows for the 
development of patient-specific cells.[82] First 
described by Takahashi and Yamanaka[83] 
in 2006, efforts are being made to develop 
robust, chemically driven protocols to differ-
entiate iPSC into nearly every cell type in the 
body.[82] As iPSC derivation and differentia-
tion technologies have developed, so too has 
their use in hydrogel-based TE strategies. For 
example, in a composite bioprinting strategy, 
a nanofibrillated cellulous alginate bioink 
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Figure 7. Potential strategy for in situ bioprinting. Schematic illustration showing a potential 
strategy for in situ bioprinting of tissue-specific hydrogels with different cell types to treat a 
nonunion in the radius. Multiple hydrogels could potentially be employed to reconstruct com-
plex,	multicellular	tissues	like	bone.	A)	An	acellular	hydrogel	 is	printed	to	act	as	a	structural	
support while the bone heals. B) A cell-laden hydrogel with tissue-specific architecture and 
biological factors is printed to promote ossification. C) Other cell-laden, biologically targeted 
hydrogels	could	also	be	simultaneously	printed	to,	for	example,	promote	vascularization	or	aid	
in tissue remodeling.
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could successfully drive chondrocyte-derived iPSC to form car-
tilage-like tissue.[84]
Cartilage TE only requires incorporating chondrocytes into a 
scaffold; however, for more complex tissues, multiple cell types 
are often necessary. Inkjet printing has been used to incorporate 
multiple cells types into hydrogels with precise spatial control.[85] 
This was achieved in an alginate–collagen composite hydrogel 
system by loading different cell types (human amniotic fluid-
derived stem cells, smooth muscle cells, and endothelial cells) 
into separate bioink cartilages. Using a drop-by-drop method, 
cells could then be directly printed to form a complex hetero-
geneous construct.[85] When implanted in a mouse model, con-
structs were shown to have adequate vascularization, which had 
previously been a hurdle for generating functional bone tissue.[85] 
Another strategy to address the issues of vascularization is 
coprinting. This strategy has been pursued whereby different 
cell types, vasculature, and ECM bioinks have been coprinted to 
form complex heterogeneous structures[86] and vascularized tis-
sues as thick as 1 cm.[87] In this technique, silicon ink is initially 
printed to create a customized perfusion chip. Cell-laden inks are 
then printed alongside a temporary fugitive ink, encapsulated in 
a castable ECM. Following casting, the fugitive ink is removed 
leaving behind a vascular network of interconnecting chan-
nels.[87] Tissue constructs printed in this manner demonstrated 
greater perfusion and survived longer culture times (6 weeks vs 
14 d) than previous efforts.[86,87]
3.4. Incorporating Cell-Responsive and Dynamic Properties
Mechanical properties of tissues and biomaterials clearly 
play a role in directing cellular responses such as differen-
tiation. However, in native tissues, many properties, including 
mechanical properties are dynamic. For example, during chick 
development, the tissue that arises from the mesoderm that 
is destined to become the adult heart stiffens from an elastic 
modulus of 0.9 to 8.2 kPa between 36 and 408 h postfertiliza-
tion.[88] Dynamic properties such as this can be incorporated 
into hydrogels using a number of strategies. Young and Engler, 
for example, matched the stiffening of their thiol-modified HA 
hydrogels to that of the dynamic properties of the chick heart. 
They found that dynamic hydrogels upregulated the expression 
of mature cardiac markers when compared to cells grown on 
soft, but static polyacrylamide hydrogels.[88]
Other methods to incorporate dynamic properties into hydro-
gels include exploiting supramolecular chemistry and self-
assembly strategies. For example, by incorporating specific pep-
tides, hydrogels can be designed to respond to physical stimuli, 
such as light and temperature, as well as chemical and biolog-
ical stimuli, such as pH or enzyme cleavage.[52,89] Promising 
work by Stupp and co-workers has shown that supramolecular 
nanofibers are able to effectively delivery the growth factor 
BMP-2 for bone regeneration.[90] Peptide sequences can also 
be used to mimic complex biological factors such as vascular 
endothelial growth factor (VEGF).[91] Moreover, work by Silva et 
al. showed that high density presentation of a laminin-derived 
epitope on supramolecular nanofibers could selectively differen-
tiate neural progenitors into neurons.[92] Indeed, incorporation 
of such supramolecular materials into hydrogels for controlled 
delivery may enable the development of dynamic systems in 
which the materials themselves are capable of adapting to their 
surrounding environment.
In addition to supramolecular materials, researchers are also 
exploring dynamic materials based on 4D biomimetic printing. 
For example, researchers have used cellulose fibrils to print 
anisotropic swelling behavior into hydrogels that change their 
shape as a function of time following immersion in water.[93] 
The authors used this system to create nature-inspired 3D 
shapes, such as that of the Dendrobium helix, a stunning orchid 
native to the lowlands of New Guinea. However, such tech-
nologies could also potentially be applied to bioprint tissues 
with mesoscale structures that form upon immersion in bio-
logical fluids.[93] While 4D biomimetic systems for regenerative 
applications have not yet been reported, we envision a future 
that would utilize such technologies for clinical applications. 
For example, there has been much effort devoted to creating 
TE heart valves to replace stenotic or damaged values resulting 
from disease or congenital conditions. However, such advanced 
therapies would likely still require traumatic and dangerous 
open-heart procedures to surgically implant them. A 4D bio-
printed heart valve, on the other hand, may allow for the future 
development of minimally invasive heart valve repair whereby 
a new valve could be inserted via a catheter and formed in situ 
in the heart. Similarly, maxillofacial surgeries to repair orbital 
floor fractures, common in patients in motorbike accidents, 
are often necessary to prevent enophthalmos, but can suffer 
from complications sometimes associated with the surgical 
placement of alloplastic implants.[94] Here, a future in which 
4D-bioprinted constructs, fabricated to match a patient’s own 
facial structures based on high-resolution imaging, and placed 
in a minimally invasive procedure prior to assuming their full 
shape, are feasible.
4. Acellular Hydrogel Approaches
As cell-based therapies such as TE offer numerous possibilities 
for tissue regeneration, there is good reason for excitement sur-
rounding their development. However, cell-based therapies face 
significant challenges in terms of cost, regulatory hurdles, and 
scalability.[95,96] Cell free therapies, on the other hand, are often not 
as limited in their path to clinical translation because they tend 
to be less complex. Traditionally, acellular biomaterials have been 
used simply as fillers and for structural support, however, a new 
generation of acellular hydrogels are being designed to interact 
with endogenous factors, including local tissue and cells, to aid 
with healing and promote tissue regeneration (Figure 8).[95,97]
4.1. Hydrogels as Controlled Delivery  
Vehicles for Bioactive Molecules
The fundamental approach of many acellular biomaterial 
strategies is to trigger tissue regeneration in situ by uti-
lizing the body’s own regenerative capabilities. This is often 
achieved by mobilizing host tissue progenitors to the site of 
injury or prompting nearby cells to mediate repair. The con-
cept of biomaterial-driven tissue regeneration is not new and 
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many biomaterials have been designed to deliver biological 
molecules such as growth factors and cytokines to stimulate 
matrix production and cell growth. There are many excellent 
reviews available on this subject; therefore, we will only com-
ment on a limited number of strategies here.[98]
One of the most well-known drug delivery platforms based on 
a biomaterial is Medtronic’s INFUSE system, which comprises 
a collagen type I biomaterial that releases recombinant human 
BMP2, and is placed surgically to treat long bone fractures and 
in spinal fusion procedures.[99] Although the INFUSE system has 
been highly criticized for causing side effects such as inflamma-
tion when used in off-label procedures,[100] the fundamental idea 
of using a biomaterial to deliver an active biological molecule is 
widespread. Indeed, many issues associated with the off-label use 
of INFUSE arose from the high dosage of growth factors rather 
than delivery strategy itself.[100] Cardiac stents have been similarly 
designed to elute drugs that can prevent re-stenosis of coronary 
arteries,[101] and wound dressings which release antibiotics and 
growth factors to aid healing are widely described.[102]
Hydrogels provide an attractive system for the delivery of 
biological molecules, as in addition to good biocompatibility 
and amenability for minimally invasive delivery, they are also 
highly physically and chemically modifi-
able,[98] which can allow for precise control 
of release of biological molecules over min-
utes, hours, days, and perhaps even years. 
Most commonly, this release rate is mediated 
via diffusion, which can be easily controlled 
by varying either the hydrogel’s network size 
or degradation rate.[98] One strategy to con-
trol hydrogel degradation involves a similar 
strategy to that used to create degradable 
ex vivo tissue models: cross-linking hydro-
gels with peptides that are susceptible to 
cleavage by MMPs.[103] For example, MMPs 
are important in heart tissue homeostasis, 
but in specific cardiovascular diseases exces-
sive MMP production can lead to inflam-
mation and tissue damage. Purcell et al. 
exploited this tissue response with a polysac-
charide-based hydrogel that electrostatically 
sequestered a recombinant MMP inhibitor. 
The hydrogel was then cross-linked with 
MMP-cleavable peptides such that cleavage 
of the peptides mediated the release of the 
MMP inhibitor.[104] When placed in a porcine 
model of myocardial infarction, the hydrogel 
was effective in reducing adverse left ventric-
ular remodeling.[104]
As our understanding of the biological 
mechanisms of tissue regeneration con-
tinue to grow, so too has the development of 
hydrogels that aim to exploit them. One way 
this has been pioneered is through under-
standing the paracrine mechanisms by which 
stem cells can stimulate tissue regenera-
tion. For example, MSC appears to mediate 
regeneration via release of paracrine fac-
tors rather than de novo regeneration.[105]  
Hydrogels provide an exciting opportunity in this context as 
they can allow for the controlled delivery of cell-derived regener-
ative factors, such as exosomes, without the regulatory hurdles 
of delivering cells themselves. This was demonstrated recently 
by Tao et al. who employed a chitosan hydrogel that medi-
ated sustained release of MSC exosomes. When tested in a rat 
model, the material accelerated skin wound healing.[106]
4.2. Exploiting Hydrogel Physical Properties  
to Direct Host Cell Response
In addition to releasing bioactive factors that can regulate 
regeneration, researchers are also developing hydrogels with 
physical properties, such as stiffness, degradability, and topog-
raphy, that are matched to those of the native tissue or can 
recruit and/or direct cells in regeneration.[107,108] One area in 
which this has been particularly successful is in CNS regenera-
tion, as hydrogels can be designed to have similar mechanical 
properties to those of the brain.[108] HA-based hydrogels with 
elastic moduli in the range of 3–10 kPa have been shown to 
be optimal for neural progenitor cell (NPC) differentiation.[109] 
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Figure 8. Using acellular hydrogels to promote tissue regeneration. For regenerative strategies 
based on acellular hydrogels, various factors can be incorporated into the hydrogel. Such fac-
tors	may	include	growth	factors,	regenerative	exosomes,	or	microRNA,	which	will	be	released	
over time as the hydrogel degrades. Acellular hydrogels can also be used to directly instruct 
host	cells.	For	example,	tissue-specific	ECM	or	topography	can	also	be	incorporated	into	the	
hydrogel to direct host stem cell differentiation as cells come in contact with it. More advanced 
acellular hydrogel strategies might incorporate controlled spatial and temporal release of spe-
cific factors. Using cleavable systems such as those mediated by MMP activity, factors will 
only be released in response to cell- or tissue-specific stimuli. This could be particularly useful 
for tissue interfaces such as the Achilles tendon-bone insertion (enthesis), where the spatial 
distribution of biological factors is key in modulating cell behavior.
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NPC encapsulated in soft hydrogels that mimicked the stiff-
ness of a neonatal brain (≈2.6 kPa) differentiated into neurons. 
However, when encapsulated in slightly stiffer hydrogels, more 
akin to that of adult brain (≈5.7 kPa), NPC differentiated into 
astrocytes.[109] For CNS regeneration, hydrogel degradation is 
also key. Silk-based hydrogels have been shown to be advanta-
geous in this context as they have slow degradation rates that 
may foster neural regeneration.[110]
Other physical features of hydrogels can also be exploited 
to direct host cells. In addition to degradability, cell infiltration 
into an acellular hydrogel will also depend on hydrogel porosity/
mesh size, the availability of cell adhesive motifs—often adhe-
sive peptides, syndecans,[111] or cadherins[112]—and the hydrogel’s 
amenability to promote the formation of a vasculature. Cells need 
to be within ≈100 to 200 µm of a blood vessel in order to receive 
enough nutrients and oxygen for normal function.[113] Hydrogel 
architecture appears to play an important role in modu lating this. 
Chiu et al.[114] showed that pore sizes within PEG hydrogels 
between 50 and 150 µm in diameter allowed for the formation 
of vasculature, while pore sizes of 25–50 µm limited vessel infil-
tration.[114] Micropatterning techniques have also been exploited 
to guide cell migration in acellular hydrogels. Lee et al. demon-
strated a photo laser scanning photolithography technique in 
which RGD sites could be patterned into a collagenase-sensitive 
poly(ethylene glycol-co-peptide) diacrylate hydrogel to direct cell 
migration.[115] They showed that cell migration along patterns 
promoted successful wound healing.
4.3. Hydrogels with Immunomodulatory  
and Gene Therapy Functionality
The immune system plays an important role in tissue repair and 
is emerging as a key target of biomaterial-based regenerative 
strategies. Some biomaterials are known to interact directly with 
particular aspects of the immune system.[116] HA, for example, 
has anti-inflammatory properties, while natural materials such 
as chitosan scavenge free radicals, which can then reduce/sup-
press inflammation.[116,117] Indeed, active control of the immune 
system may be key in modulating tissue repair and regenera-
tion. Inflammation is an essential response to injury, and plays 
a central role in initiating healing.[116] During normal healing, 
acute inflammation is followed by a resolving anti-inflammatory 
response, and the restoration of tissue integrity.[116] Issues arise 
if inflammation becomes chronic and inhibits healing.[118] This 
scenario provides an opportunity for hydrogels with dual func-
tionalities that can help mediate these responses. For example, an 
initial hydrogel-based delivery of a proinflammatory signals such 
as SDF-1 (an inflammatory and angiogenic cytokine) might aid 
in the mobilization of progenitor cells.[119] This response could 
then be followed by the release of anti-inflammatory media-
tors such as IL-4 and IL-10, which are key for tissue repair as 
they trigger macrophages to switch from a proinflammatory to 
a reparative phenotype.[120] Similarly to the MMP-cleavable sys-
tems that have been exploited to treat the effects of myocardial 
infarction,[104] such systems could be designed to release a pro-
inflammatory molecule until an appropriate response from the 
native tissue triggers release of an antiinflammatory molecule to 
resolve tissue healing.
In addition to releasing inflammatory molecules, hydro-
gels can also be used to modulate the host’s immune system. 
For example, biomaterials can be used induce an antigen-
specific tolerogenic response to treat a variety of autoimmune 
diseases.[121,122] This was demonstrated by Verbeke et al. who 
used an alginate hydrogel to deliver a peptide antigen mimotope 
to treat type 1 diabetes in a mouse model. This peptide hydrogel 
delivery system resulted in expansion of antigen specific T cells 
in the lymph nodes.[122] Beyond treating autoimmune diseases, 
similar therapies could also be used to modulate transplant 
rejection.[122]
Gene therapy technologies similarly hold great promise for 
regeneration.[123] With such therapies, successful delivery is 
vital, making hydrogels an attractive platform to locally and sus-
tainably deliver appropriate molecules. For example, Yang et al. 
used a PECE thermoresponsive hydrogel to deliver an antionco-
gene. This system was capable of sustainably and locally deliv-
ering the gene, which was important for maximizing its antitu-
mour effects, but minimizing systemic side effects.[124] Hydro-
gels have also proven useful as lentiviral delivery systems, and 
there is evidence that they both increase the stability of the 
virus as well as help protect it from the immune system.[125] 
Indeed, for lentiviral gene therapy, host immune response 
can affect efficacy. Hydrogels with small pore sizes can limit 
complement and antibody diffusion, potentially protecting the 
virus.[125] Hydrogels have been used for the delivery of nucleic 
acids to treat spinal cord injury.[126] Aligned nanofiber hydrogel 
scaffolds were shown to sustainably release microRNAs that 
enhanced axon regeneration.[126] Scaffold design here medi-
ated alignment of the fibers by providing topographical cues to 
direct neurite extension.[126] With the development of CRISPR/
Cas9 systems, hydrogels may also have the potential to play an 
important role in genome editing technologies in the future.
5. Hydrogel Delivery Strategies
While researchers exploit hydrogel technologies to under-
stand how biochemical and biophysical cues influence cell and 
tissue function to create 3D tissue models and TE platforms, 
being able to exploit these cues with hydrogels depends upon 
our ability to deliver them for appropriate therapeutic applica-
tions (Figure 9). Simple implantation of biomaterials through 
traditional surgical means is a standard delivery route. How-
ever, surgery can lead to morbidity at the implantation site, is 
associated with surgical and recovery costs, and will almost 
always cause patient discomfort.[127] For example, to treat osteo-
chondral defects on the articulating surfaces of the knee, early 
hydrogel implants (such as Cartipatch, an alginate-based con-
struct) required surgery, which could cause inflammation and 
increased the chance of infection, which could result in treat-
ment failure.[128] To overcome these drawbacks there have been 
significant efforts to design injectable, in situ forming, and 
nano/microhydrogel systems that can be delivered in a mini-
mally invasive manner.
For any hydrogel-based therapeutic to be a viable clinical 
option, the cross-linking/gelation mechanism must be bio-
logically mild as to not damage the surrounding tissue or 
biologics, including cells, in the hydrogel. Injectable hydrogels 
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that have been developed for tissue repair employ various gela-
tion methods that are mediated through chemical or physical 
interactions. Deciding which gelation mechanism to use 
depends on the application and the desired effect. Chemical 
interactions are covalent bonds formed between precursors 
that cross-link the hydrogel. Covalently formed hydrogels are 
often robust and mechanically strong. For example, Michael 
addition reactions between thiol groups and acrylates or meth-
acrylates have been employed to form covalently cross-linked 
hydrogels and are often aided by UV light.[129] Physical interac-
tions, on the other hand, lead to hydrogels that have reversible 
bonds between hydrogel components, and are achieved using 
molecular interactions like hydrophobic interactions, π–π 
interactions, hydrogen bonding, metal chelation, and van der 
Waals interactions.[52] Covalent cross-linking typically requires 
physical initiators while noncovalent cross-linking often 
arises spontaneously under specific conditions.[108] A combi-
nation of both covalent and physical interactions in the same 
hydrogel has also been explored[130,131] to create hydrogels for 
cartilage[132] and cornea repair.[133] For example, a network that 
contains both rigid and ductile components can be mechani-
cally advantageous because the rigid network can sustain 
load, while the ductile network dissipates energy, preventing 
failure.[130] Indeed, Shin et al.[130] created a hydrogel that 
was made of a covalently linked gellan gum network, which 
had a second covalently linked gelatine network incorporated 
within it. This biocompatible, double network could be loaded 
with cells, and showed excellent load-bearing properties, 
approaching those of native articular cartilage.
5.1. Injectable Hydrogels Cross-Linked by Light
UV irradiation-induced cross-linking is a common approach to 
covalently cross-link hydrogels or activate biologics in hydrogels 
in situ.[134–136] UV cross-linking allows quick gelation within 
seconds[137] to minutes.[138] This characteristic is important as 
it provides a means to quickly solidify a liquid precursor, which 
otherwise may be diluted by blood or other body fluids. As well 
as possessing quick gelation times, UV-cross-linkable hydrogels 
can be designed with low molecular weight, and thus low-
viscosity, precursors. This is advantageous because it allows 
the hydrogel to be injected and then take the shape of a defect 
or cavity prior to cross-linking. This space filling property may 
be crucial for proper integration with surrounding tissues and 
regeneration.
Many types of biological and synthetic molecules/ 
polymers can be delivered and cross-linked via light, including 
polyethylene glycol,[139] poly(2-hydroxyethyl methacrylate),[140] 
modified HA,[141] and modified chitosan.[142] The ability to cova-
lently incorporate various moieties to mediate cross-linking and/
or incorporate biological components is commonly achieved by 
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Figure 9. Various strategies for hydrogel delivery. Schematic diagram showing a range of strategies for hydrogel delivery and gelation. A) Single cells 
can	be	encapsulated	in	thin	hydrogels,	which	can	then	be	injected	intravenously	to	be	distributed	throughout	the	body.	The	hydrogel	coating	can	be	
designed	to	protect	the	cells	from	the	immune	system.	B)	Hydrogels	can	be	covalently	cross-linked	by	enzyme-mediated	reactions	between	reactive	
groups on the hydrogel monomers, forming a network. C) Noncovalent cross-linking of hydrogels can be achieved via hydrophobic, interactions, π–π 
interactions, hydrogen bonding, metal chelation, or van der Waals interactions. These hydrogels can sometimes be shear thinning, which makes them 
easily	injectable	and	may	also	protect	encapsulated	cells	during	the	injection	process.	D)	Hydrogels	can	be	used	as	cornel	implants	and	keratopros-
theses.	E)	UV	light	can	be	used	to	cure	hydrogels	subcutaneously	after	injection	or	activate	biological	moieties	like	cell-adhesion	peptides,	providing	
spatiotemporal control of their biological activity. F) Surgical implantation of a hydrogel to treat a nonunion fracture. G) Micro- and nanohydrogels, 
with	or	without	cells,	can	be	delivered	via	IV	injection.	H)	Hydrogel	patches	with	encapsulated	cardiac	stem	cells	can	be	surgically	implanted	to	treat	
myocardial infarction.
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attaching acrylate, vinyl, methacrylate, or thiol groups to these 
molecules or taking advantage of similar side groups. UV irradia-
tion-inducible cross-linking is often facilitated by non-toxic photo 
initiators like Irgacure 2959,[143] which is part of the free radical-
dependent Michael addition that polymerizes the hydrogel via 
the incorporated acrylate, vinyl, methacrylate, or thiol groups. UV 
irradiation can also be used to spatially control specific features 
like stiffness[144] and the presentation of bioactive molecules.[145]
The versatility and adaptability of light-mediated cross-linking 
make it particularly attractive when developing hydrogel-based 
therapies for in vivo use. Lin et al.[146] engineered an inject-
able, cell-laden hydrogel based on methacrylated gelatine. After 
subcutaneous injection, the hydrogel was rapidly cross-linked 
via UV irradiation and Irgacure 2959 through the skin. After 
7 days, the hydrogels supported the formation of a stable vas-
culature if endothelial colony-forming cells or MSC were incor-
porated. UV-curing hydrogels have also been explored to cross-
link an injectable hydrogel transdermally to deliver model pro-
teins in a mouse model.[134]
While UV irradiation can be used to cross-link hydrogels in situ, 
Lee et al. have shown how a similar technique can be used to acti-
vate bioactive components in an implantable hydrogel.[147] This was 
achieved with a PEG-based hydrogel modified with RGD sequence-
containing peptides that were protected by a 3-(4,5-dimethoxy-2-
nitrophenyl)-2-butyl ester photolabile caging group, which could 
be released upon exposure to UV light. Using this chemistry, they 
spatially and temporally activated the RGD peptides using precise 
and timed exposure to UV light that released the molecular cage. 
In a transdermal mouse model, the application of UV light was 
able to regulate cell adhesion, inflammation, fibrous encapsula-
tion, and vascularization.[147] This spatiotemporal control may 
have important implications for researchers’ ability to direct tissue 
repair because it has the potential to allow for the controlled 
formation of vasculature and tissue heterogeneity.
Nevertheless, while UV-mediated cross-linking has numerous 
advantages, including that it allows for fast, spatial, and temporal 
control of gelation, UV light curing methods may impact cell 
viability and negatively affect surrounding host tissue due to the 
formation of radicals, and to a lesser extent, from the UV light 
itself.[134,143,148] This method is also limited by the depth UV irra-
diation can travel through tissue and the amount of UV exposure 
and radicals a tissue can withstand without damage. Indeed, UV-
induced gelation is unlikely to see applications deep in tissues. 
To overcome potential toxicity associated with UV light curing 
methods, systems which employ visible light to initiate cross-
linking have also been developed.[149] For example, Fu et al. devel-
oped a heparin/PEG-based visible light (525 nm) cross-linkable 
hydrogel that uses eosin Y and triethanolamine as photoinitia-
tors. In this system, thiolated-heparin was cross-linked with PEG 
diacrylate through a Michael-type addition to form a covalently 
cross-linked network. Encapsulated fibroblasts remained viable 
in these hydrogels and growth factor loading was comparable to 
that achieved in other heparin-based systems.[150]
5.2. Stimulus-Driven In Situ Forming Hydrogels
Another approach to deliver therapeutic hydrogels is by 
harnessing their potential for in situ cross-linking. Unlike 
UV irradiation-induced cross-linking systems, which use 
external stimuli, in situ forming hydrogels rely on specific phys-
iological conditions (pH/temperature),[151] delayed/secondary 
cross-linking mechanisms,[136] or enzyme-mediated cross-
linking[152] to trigger hydrogel formation. This type of delivery 
approach has many of the benefits of UV cross-linked systems, 
like injectability, and fast gelation, but often lacks amenability 
for spatiotemporal control of gelation. Some key advantages of 
the in situ forming hydrogels are their ease of use in surgery 
as well as their adaptability to various applications, such as in 
deep tissues where light-mediated methods are not feasible.
Enzymatically cross-linked hydrogels are one promising form 
of in situ cross-linked hydrogels. These hydrogels are polymer-
ized through the catalytic activity of enzymes added exogenously, 
which facilitate the covalent bonding between two substrates that 
are linked to larger molecules that comprise the bulk hydrogel. 
Enzymes that have been explored to induce gelation include 
transglutaminase, tyrosinase, phosphopantetheinyl transferase, 
lysyl oxidase, plasma amine oxidase, phosphatases, thermolysin, 
β-lactamase, phosphatase/kinase, and peroxidases.[153] Enzymes 
of particular interest are transglutaminases, which cross-link via 
the formation of ε-(γ-glutamyl)lysine bonds or the incorporation 
of primary amines with glutamine residues.[154] Transglutami-
nases are advantageous because they can facilitate a tight inte-
gration of the hydrogel with the surrounding host tissue. This 
tight integration between the native tissue and hydrogel is due 
to the readily available naturally occurring substrate for transglu-
taminases, which exists in native tissues.[155]
A novel use of enzyme-mediated cross-linked hydrogels was 
recently reported by Griffin et al.,[156] who engineered PEG-
based microhydrogel beads that were modified by covalently 
attaching glutamine and lysine. These molecules can act as 
substrates for factor XIII, a transglutaminase enzyme involved 
in blood coagulation. Upon addition of exogenous factor XIII, 
the hydrogel beads were cross-linked via reactions between the 
primary amine on the lysine with the glutamine to produce 
porous hydrogels that human dermal fibroblasts, adipose-
derived MSC, and bone marrow-derived MSC could infiltrate. 
The authors also injected these materials into a mouse skin 
wound model and cross-linked them with exogenous factor 
XIII in situ to form a porous scaffold. Wounds treated with the 
cross-linked microhydrogels showed faster wound closure and 
decreased inflammation compared to those treated with a non-
porous hydrogel made of the same material. Other groups have 
also used enzyme cross-linked hydrogels for cartilage TE. For 
example, gelatin-hydroxyphenylpropionic acid has been cross-
linked with horseradish peroxidase catalyzed by H2O2 to form 
a viscoelastic hydrogel. When these enzyme cross-linked hydro-
gels were used to encapsulate chondrocytes and then injected 
into an osteochondral defect in a rabbit, improved cartilage 
regeneration was reported in comparison to that in no hydrogel 
controls.[157]
Nevertheless, while enzymatically cross-linked hydrogels 
show promise, the inclusion of exogenous enzymes may have 
unforeseen deleterious biological effects. For example, exog-
enous application of transglutaminases in vivo most likely 
also cross-links ECM proteins in the tissue surrounding the 
hydrogel, which can lead to tissue stiffening. Indeed, while 
transglutaminases are essential for many biological processes, 
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they can also contribute to the pathophysiology of various 
inflammatory, autoimmune, and degenerative conditions.[158]
5.3. Nonstimulus-Driven In Situ Cross-Linking Hydrogels
Hydrogels covalently cross-linked in situ via nonstimulus driven 
mechanisms provide another option to deliver therapeutic 
hydrogels. These hydrogels are typically composed of precursor 
components that are mixed immediately before or during injec-
tion, often rely on simple gelation mechanisms, and are easy to 
use. One in situ cross-linking method that has shown promise 
is click chemistry. Click chemistry refers to a number of dif-
ferent types of chemical reactions that are highly efficient, even 
at low concentration. This is a particular advantage for biological 
hydrogels because of the low solid content of most systems. 
Click reactions are also advantageous because of their quick 
reaction rates and biocompatible reaction conditions. Unlike 
other mechanisms, such as enzyme-mediated cross-linking, 
click reactions are highly selective chemically, meaning that they 
do not readily produce unwanted side reactions. They have also 
been shown to be compatible with cells, drugs, and proteins.[159] 
Hermann et al.,[160] for example, developed an injectable click-
based hydrogel to delay bone growth in a mouse calvarial model 
in which rapid regrowth of bone can lead to craniofacial deformi-
ties, restricted brain growth, and an increase in intracranial pres-
sure. They utilized multivalent PEG precursors that formed a 
network upon mixing via ring-strain promoted Cu-free reactions 
between dibenzylcyclooctynes and azides attached to the PEG. 
Importantly, by incorporating the BMP antagonist Gremlin into 
their hydrogel, they were able to delay bone re-growth, dem-
onstrating a potential therapy to control bone over-growth and 
reduce the risk of life threatening complications.[160]
As well as being able to form hydrogels to deliver biologics, 
click chemistry has also been exploited to construct micropo-
rous hydrogels that when formed in the presence of cells, 
create complex polymer–cell composite systems with variable 
pore sizes.[161] To accomplish this, microgels were formed via 
an inverse suspension polymerization method with either 
dibenzocyclooctyne or azide groups. When these two microgels 
were combined, they formed a covalently connected microgel 
network that could entrap cells. This microgel system provided 
tunable properties that controlled cell–material interactions and 
cell morphology.
5.4. Intravenous Delivery of Cellular Nano-/Microgels
Although there have been a plethora of clinical trials with MSC, 
it is clear that simply injecting cells intravenously limits their 
therapeutic value.[162] Injected cells often can only briefly par-
ticipate as immunomodulatory or signaling cells before they 
are cleared from the body.[163] While many of the hydrogels 
discussed so far have focused on bulk materials that provide 
physical support to cells, techniques have also been developed 
to encapsulate cells within a thin layer of hydrogel to facilitate 
cell-based therapies.[164] The goal of this approach is often to 
deliver signaling cells that can modulate immune or regen-
erative responses via paracrine signaling, or signal to other 
therapeutically relevant cells/recruit them to a specific site 
to participate in repair. For example, single MSC have been 
encapsulated with a 5.8 µm thick sodium ion cross-linked algi-
nate hydrogel coatings to form cell-containing microgel beads. 
When delivered intravenously in a mouse model, encapsulated 
cells remained in the mouse for longer and were shown to pro-
vide a longer sustained release of cell-secreted factors than cells 
injected without coating.[163]
One drawback of intravenous injection is that radially 
injected cells are often trapped in the lungs,[165] likely due to 
their size.[166] Cells coated with a thin hydrogel, however, may 
fair a better chance of evading immune system clearance as 
hydrogels can be designed to preclude cell detection or simply 
provide a physical barrier that discourages engulfment. Hydro-
gels may also provide other interesting solutions to the problem 
of pulmonary passage. By incorporating small molecules or 
biologics on the surface of cell containing microgels, hydrogels 
could passively direct encapsulated cells to an area of damage 
or disease before they reach the lungs. Hydrogels could also 
act as homing vehicles to direct therapeutically relevant cells to 
specific locations in the body.
6. Clinical Translation of 
Hydrogel-Based Therapies
The majority of the drugs and therapeutics developed for 
human use fail during their discovery and development stages. 
Indeed, only 10.4% of all candidates put through Phase I clinical 
trials eventually receive approval for use in humans.[167] For more 
than 20 years now, TE-based therapies have been proposed and 
pushed through the development stages toward clinical trans-
lation in the hope of creating functional tissues to replace 
those lost to disease or injury.[168] As of July 2017, there were 
371 clinical trials registered worldwide that related to hydrogels 
and 69 that focused on TE (www.clinicaltrials.gov). Although 
only a handful of these studies aimed to apply recent advances 
in hydrogels to TE, there have been some limited successes, 
particularly for planar and hollow organs, such as skin, cornea, 
urethra, urinary bladder, and blood vessels.[169] However, the 
development of TE-based regenerative strategies for more 
complex tissues still faces a number of key challenges.[168,170] 
These include: (1) provision of adequate oxygen and nutrients 
to large tissues, which likely require the formation of a com-
plex vasculature; (2) incorporation of multiple cell types with 
precise spatial arrangements; (3) achievement of appropriate, 
tissue-specific mechanical properties (such as stiffness, shear 
strength and hardness); and (4) integration of TE constructs 
with surrounding tissue. Hydrogel-based TE scaffolds offer the 
possibility of addressing many of these challenges and perhaps 
can be successfully translated into viable therapies. We high-
light some promising preclinical and clinical studies that have 
exploited hydrogels for TE-based therapies below.
6.1. Cartilage Repair
Articular cartilage is an obvious target for clinical repair using 
hydrogel technologies. The market for cartilage repair is 
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tremendous given that 13.8% of the adult population over 
the age of 60 suffers from osteoarthritis, a number that will 
increase as the global population ages.[171] Articular cartilage 
is amenable to TE strategies because it lacks some of the chal-
lenges of more complex tissues because it is, for the most part, 
avascular, aneural, and only contains a single type of cell. Much 
research has been undertaken with hydrogels to regenerate car-
tilage,[172] including using naturally derived ECM-based hydro-
gels such as type I collagen, and thermoresponsive hydrogels 
formed from chitosan/PVA composites. There are also reports 
of efforts to engineer cartilage with synthetic hydrogels,[173] 
including one based on a PLGA–PEG–PLGA hydrogel.[174]
One particularly promising clinical application of a synthetic 
hydrogel for cartilage repair was reported by Sharma et al. in 
2013.[4] They developed a photoreactive, adhesive, PEGDA-
based hydrogel, which they injected into focal cartilage defects 
in the medial femoral condyle of 15 patients in conjunction 
with standard microfracture surgery. Although the injected 
hydrogel itself was acellular, the concomitant microfracture sur-
gery allowed autologous cells to invade into the hydrogel. When 
compared to outcomes in patients treated with microfracture 
alone, those who received the hydrogel-based therapy showed 
greater tissue fill and increased tissue organization (both by 
MRI). Patients also reported less pain, an important clinical 
outcome in this patient group. Although long-term follow-up 
is required to determine if the benefits of the treatment persist, 
and importantly, if the treatment ultimately prevents patients 
with focal lesions from going on to develop osteoarthritis, 
results appear promising.
A number of preclinical trials in cartilage regenera-
tion using hydrogels have also been reported. For example, 
researchers incorporated kartogenin and MSC into a syn-
thetic PLGA–PEG–PLGA hydrogel and showed good cartilage 
repair in a rabbit model.[174] Similarly, a hydrogel formed from 
oligo[poly(ethylene glycol)] fumarate combined with encapsu-
lated MSC, was reported to mediate a more hyaline-like repair 
than implantation of the scaffold alone in a porcine model.[175]
6.2. Cardiovascular Regeneration
The other application of hydrogels for TE that dominates pre-
clinical and clinical trials is for cardiovascular applications. Car-
diovascular diseases place a tremendous burden on society and 
are the leading cause of mortality worldwide.[176] Particularly in 
the United States and Europe, around 5% of the acute hospital 
admissions are due to cardiac events, and 10% of hospitalized 
patients suffer from some form of cardiovascular disease.[176]
In a completed Phase I study (NCT00981006), a gelatin 
hydrogel sheet that allowed for the controlled release of bFGF 
(200 µg) was combined with autologous cardiac-derived stem 
cells (5 × 105 cell kg−1) to treat six patients with ischemic cardio-
myopathy following acute myocardial infarction.[177] In this 
study, Takehara et al. showed that the therapy was safe and 
feasible. However, while some benefits were noted 6 months 
posttreatment, the sample size was too small to conclude 
efficacy.[177] Similarly, a phase I clinical trial (NCT02057900) 
led by Assistance Publique–Hôpitaux de Paris investigated the 
feasibility of human embryonic stem cell (ESC)-derived 
CD15+ Isl-1+ progenitors embedded within a fibrin hydrogel 
patch to treat patients with ischemic heart failure.[178] In this 
study, a fibrin hydrogel patch was used, as it had been shown 
previously in animal models to play an essential role in 
improving cell retention and survival.[179] While no conclusions 
could be drawn on efficacy, overall patient functional outcomes 
were promising.[178]
Despite some promising results, the overall efficacy of car-
diovascular cell therapies is inconclusive. A meta-analysis that 
examined treatments for heart failure showed that among 31 
randomized cell therapy trials comprising 1521 patients, exer-
cise capacity, left ventricular ejection fraction, and quality of 
life were all improved in the treated patients.[180] However, 
a second meta-analysis that examined patient data from 12 
trials could find no benefit of intracoronary cell therapies in 
treating acute myocardial infarction.[181] Such conflicting data 
raise concerns about cell-based therapies for cardiovascular 
diseases and highlight the need for improved strategies. For 
future treatments, multidisciplinary approaches may provide 
an answer. Cell retention in cardiac tissue, for example, is 
thought to be important, and hydrogels have the capability to 
improve this.[182] Successful differentiation into mature car-
diomyocytes is likely also key, and again, could be aided by 
careful scaffold design. Indeed, many cell types are known to 
be mechanoresponsive, including cardiomyocytes. Work by 
Morez et al. showed that modifying material surface topog-
raphy by creating microfabricated grooves could promote car-
diac progenitor elongation and alignment, driving appropriate 
differentiation.[183] Cell-containing cardiac patches that rely 
on bioprinting technologies are similarly promising. Using a 
bioprinting strategy, precise patterns of human umbilical vein 
endothelial cells and hMSC were created; and when implanted 
in a rat model of myocardial infarction, led to increased 
angiogenesis and improved cardiac function in comparison 
to patches in which cells were seeded randomly.[184] Another 
consideration for successful treatment of myocardial infarc-
tion is delivery time. A disadvantage of patch-based delivery 
systems is that they often require surgical procedures. Inject-
able hydrogels, on the other hand, can be delivered quickly 
to the site of injury.[185] Indeed, injectable hydrogels could be 
delivered minimally invasively as transcoronary infusions or 
transendocardial injections.[185] Such fast delivery of cells/scaf-
folds may help prevent damage to the heart tissue postinfarc-
tion. While no such injectable hydrogel systems have been 
used clinically, future developments in dynamic, injectable 
hydrogels may make this achievable.
7. Conclusions
Over the last decade, hydrogel technologies have improved 
dramatically allowing researchers to create ex vivo tissue 
models that replicate that native tissue better than ever before. 
Researchers are also developing hydrogel-based biomaterials 
with controlled architectures and biological and physical prop-
erties that can be used for TE. Moreover, acellular hydrogels 
that can deliver bioactive molecules are increasingly finding 
use in drug delivery applications, often relying on their inject-
ability and chemistries that allow for in situ gelation. Taken 
Adv. Healthcare Mater. 2018, 1700939
www.advancedsciencenews.com www.advhealthmat.de
1700939 (19 of 22) © 2018 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
together, the result is a toolbox of hydrogel-based materials 
that can be used by both bench-based researchers to answer 
fundamental questions in cell biology, and physicians to either 
replace damaged tissues or deliver cells/molecules to mediate 
repair. Indeed, the advancements in regenerative medicine that 
these new hydrogel technologies are likely to foster are surely 
something to feel “swell” about.
Despite such exciting developments, however, developments 
in hydrogel research only seem to trickle into a few limited clin-
ical applications. This may be partly attributable to regulatory 
and funding limitations, but may also be because of risk. Tissue 
regeneration is clearly a complex process, which will require com-
plex biological and material-based strategies to tackle. Indeed, it is 
likely that only through careful consideration of the both the target 
tissue’s biological, physical and mechanical properties can hydro-
gels be developed that can truly mediate or participate in regen-
eration. However, as fundamental research in cell biology reveals 
how cells respond to their ECM and their niche, and new insights 
into endogenous tissue regenerative mechanisms are identified, 
materials scientists and chemists will inevitably develop hydro-
gels that can exploit and target them for regeneration.
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